Shots:

• The P-III EXCEED study involves assessing Cosentyx (300mg) vs Humira (adalimumab- 40 mg) in 800+ biologic-naïve patients with PsA for 52wks.
• The P-III EXCEED results: Cosentyx narrowly missed statistical significance for superiority in ACR 20 but showed significant advantages in PsA specific endpoints- observed in a pre-specified sensitivity analysis- no new safety signals were observed
• Cosentyx is a mAb- selectively targeting IL-17A and is indicated to treat mod. to sev. plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy- for patients with active psoriatic arthritis and active ankylosing spondylitis

Click here to­ read full press release/ article | Ref: Novartis | Image: Money Control